HOME >> MEDICINE >> NEWS
Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years

ffect the nose, but patients also report itchy, watery eyes, sneezing and nasal congestion. SAR often remains undiagnosed and untreated because people mistake their symptoms as related to a "cold" or the "flu."

What Is Chronic Idiopathic Urticaria (CIU)?
Chronic idiopathic urticaria (CIU), is caused by a reaction to an unknown trigger in the upper layers of the skin. Its primary symptom is the formation of itchy hives that last less than 24 hours but can recur frequently for six weeks or longer. The cause of CIU cannot be discovered in at least 75% of cases.


'"/>

Contact: Charles F. Rouse III
973-394-6050
Porter Novelli
4-Jun-2000


Page: 1 2 3

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Aventis Pasteur statement on HVTN 501 decision
4. Millennium, Aventis Pharma form novel alliance
5. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
6. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
7. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
8. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
9. Pharmaceuticals and personal care products
10. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
11. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis

Post Your Comments:
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Not getting the ... ulcerative colitis, a new study suggests. Those who ... eight hours per night may be more prone to ... intestines, researchers report. The study authors concluded that duration ... considered among patients with inflammatory bowel diseases. "Both ...
(Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research ... and Drug Administration (FDA) has given the company permission ... AS2-1 in patients > 3 months of age with ... be placed in one of five treatment groups based ... received prior treatment for DIPG. The primary study endpoint ...
(Date:10/22/2014)... 22, 2014  Cephasonics, a technology-innovation leader with a ... cQUB™-1 (cQuest Ultrasound Box™-1), the first product in a ... manufactured by Cephasonics for purchase by companies to rebrand ... will be showcasing the cQUB-1 for the first time ... Chongqing, China from October 23 ...
(Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
Cached News: